RT Journal Article
SR Electronic
T1 Effects of statin therapy on coronary plaque volume by decreasing CRP/hsCRP levels: A meta-regression of randomized controlled trials
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.26.21268412
DO 10.1101/2021.12.26.21268412
A1 Darui Gao
A1 Rong Hua
A1 Dina Jiesisibieke
A1 Yanjun Ma
A1 Chenglong Li
A1 Sijing Wu
A1 Qian Ma
A1 Wuxiang Xie
YR 2022
UL http://medrxiv.org/content/early/2022/01/10/2021.12.26.21268412.abstract
AB Background and aims Several clinical trials have indicated that statins stabilize and reverse atherosclerotic plaque. However, different studies have provided inconsistent findings regarding mechanisms and influencing factors of plaque regression under statin therapy. In this study, meta-analysis and meta-regression were used to determine the effects of statin medications on coronary plaque volume as determined by intravenous ultrasound. Meanwhile, the impact of CRP/hsCRP reduction during statin therapy on plaque regression was investigated.Methods Up to May 28, 2021, a systematic PubMed, EMBASE, and Cochrane search was performed for randomized controlled trials that assessed treatment effect using total atheroma volume (TAV), percent atheroma volume (PAV), or plaque volume (PV). Only CRP/hsCRP and LDL-C values reported before and after treatment were considered.Results 12 studies fulfilled the inclusion criteria and were included in the systematic review. A meta-analysis of 15 statin-treated arms reported a significant reduction in change of TAV/PV (standardized mean difference [SMD]: −0.27, 95% confidence intervals [CI]: −0.42, −0.12), compared with the control arms. Another meta-analysis of 7 trials also found that patients in the intervention group had a significant reduction in change of PAV (SMD: −0.16, 95% CI: −0.29, −0.03), compared with those in the control group. Meta-regression analysis revealed the percent change of CRP/hsCRP statistically influences SMD in change of TAV/PV after adjusting for percent change of LDL-C, age and gender. Meta-regression analysis showed that percent change of CRP/hsCRP statistically influences SMD in change of PAV.Conclusion In conclusion, statin therapy is beneficial for plaque regression. Statins promote plaque regression through their anti-inflammatory ability.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by he National Natural Science Foundation of China (project no. 81974490) and 2019 Irma and Paul Milstein Program for Senior Health Research Project Award.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a meta-analysis involving data from 12 previous studies in three databases(PubMed, EMBASE, and Cochrane).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.